Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF. Stephen Hodi, Jedd D. Wolchok, Caroline Robert et al.|Journal of Clinical Oncology|2016Cited by 754
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.F. Stephen Hodi, Jedd D. Wolchok, Antoni Ribas et al.|Journal of Clinical Oncology|2014Cited by 40
Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.Jedd D. Wolchok, F. Stephen Hodi, Omid Hamid et al.|Journal of Clinical Oncology|2015Cited by 20
Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)F. Stephen Hodi, Jedd D. Wolchok, Antoni Ribas et al.|Journal for ImmunoTherapy of Cancer|2014Cited by 12